Keyphrases
Receptor Targets
100%
Androgen Receptor
100%
Thrombospondin-1 (TSP-1)
100%
Tumor Growth in Vivo
100%
Prostate Tumor Growth
100%
Apoptosis
33%
Tumor
33%
Prostate Cancer
22%
Prostate Cancer Cells
22%
Androgen Ablation
22%
Testosterone
11%
Androgens
11%
Prostate
11%
Transcriptional Activity
11%
Transcription Factor
11%
Molecular Events
11%
Nuclear Localization
11%
Cancer Cells
11%
Low Dose Rate
11%
Interleukin-6
11%
Molecular Mediators
11%
Stably Expressing
11%
B-cell Lymphoma 2 (Bcl-2)
11%
Vascular Function
11%
Cancer Growth
11%
Negative Control
11%
Androgen Receptor Expression
11%
Antiangiogenic
11%
Mechanistic Explanation
11%
Tumorigenicity
11%
Anti-apoptotic
11%
Male Mice
11%
Angiogenic Proteins
11%
Pro-survival
11%
Antitumor Effect
11%
Response to Chemotherapy
11%
Androgen Signaling
11%
Prostate Epithelium
11%
Angiogenic Potential
11%
RelA
11%
Antitumor Activity in Vivo
11%
Conflicting Opinions
11%
Medicine and Dentistry
Tumor Progression
100%
Thrombospondin 1
100%
Androgen Receptor
100%
Prostate Tumor
100%
Neoplasm
36%
Prostate Cancer
36%
Programmed Cell Death
27%
Cancer Cell
27%
Androgen
27%
Chemotherapy
9%
Mediator
9%
Carisoprodol
9%
Secretion (Process)
9%
Cancer Growth
9%
Antiangiogenic
9%
Antineoplastic Activity
9%
Carcinogenicity
9%
Receptor Expression
9%
Vascularity
9%
Prostate Epithelium
9%
Antiapoptotic
9%
Drive
9%
Transcription Factors
9%
Interleukin 6
9%
Angiogenic Protein
9%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Growth
100%
Androgen Receptor
100%
Thrombospondin 1
100%
Prostate Tumor
100%
Neoplasm
45%
Prostate Cancer
36%
Androgen
27%
Chemotherapy
9%
Antiangiogenic
9%
Antiapoptotic
9%
Malignant Neoplasm
9%
Carisoprodol
9%
Cancer Growth
9%
Carcinogenicity
9%
Transcription Factors
9%
Interleukin 6
9%
Angiogenic Protein
9%
Biochemistry, Genetics and Molecular Biology
Tumor Progression
100%
Androgen Receptor
100%
Thrombospondin 1
100%
Cancer Cell
27%
Vascularization
9%
Drive
9%
Secretion (Process)
9%
Mediator
9%
Antineoplastic Activity
9%
Bcl-2
9%
Transcription Factors
9%
Interleukin 6
9%
Carisoprodol
9%